Onconetix, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
ONCO$3.47-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(4,214,875) | $(8,545,885) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Loss on impairment of goodwill | 8,134,000 | 10,918,000 |
| Amortization of debt discounts | — | 4,966 |
| Depreciation and amortization | 5,398 | 4,748 |
| Change in fair value of subscription agreement liability – related party | — | (3,319,000) |
| Net periodic pension benefit | — | (89,827) |
| Stock-based compensation | 22,305 | 29,256 |
| Gain on forgiveness of accounts payable | — | (944,694) |
| Change in fair value of contingent warrant liability | (1,612) | 9,795 |
| Change in fair value of Series D derivative liability | (3,955,778) | — |
| Change in fair value of Series E derivative liability | (2,072,590) | — |
| Disposal of property and equipment | — | 2,472 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 270,735 | 9,453 |
| Inventories | 11,654 | (91,019) |
| Investor receivable | 50,000 | — |
| Prepaid expenses and other current assets | (83,396) | 3,638 |
| Accounts payable | (224,779) | (261,362) |
| Accrued expenses | (62,543) | 269,779 |
| Net cash used in operating activities | (2,121,481) | (1,999,680) |
| Cash flows from investing activities | ||
| Net cash Provided by (used in) investing activities | — | — |
| Cash flows from financing activities | ||
| Proceeds from issuance of note payable | 247,196 | 100,000 |
| Principal payments of notes payable | — | (937,550) |
| Payment for redemption of Series C Preferred Stock | — | (1,318,813) |
| Proceeds from exercise of warrants | 384,842 | — |
| Cash in lieu of shares | (250) | — |
| Proceeds from issuance of common stock in connection with the ELOC | — | 5,026,617 |
| Net cash provided by financing activities | 631,788 | 2,870,254 |
| Effect of exchange rate changes on cash | (14,889) | 60,119 |
| Net increase (decrease) in cash | (1,504,582) | 930,693 |
| Cash, beginning of period | 5,220,654 | 646,500 |
| Cash, end of period | $3,716,072 | $1,577,193 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $— | $21,162 |
| Noncash investing and financing activities: | ||
| D&O insurance premium financed | $— | $460,875 |
| Conversion of Series D preferred stock to common stock | $22 | $— |
| Conversion of Series E preferred stock to common stock | $1 | $— |
| Deemed dividend owed to Series C preferred stock shareholders | $— | $394,757 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.